Deuterium Capital Management LLC Takes $120,000 Position in Liquidia Co. (NASDAQ:LQDA)

Deuterium Capital Management LLC acquired a new position in Liquidia Co. (NASDAQ:LQDA) during the second quarter, HoldingsChannel reports. The institutional investor acquired 10,000 shares of the company’s stock, valued at approximately $120,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of LQDA. Cerity Partners LLC purchased a new stake in Liquidia in the fourth quarter worth about $197,000. New York State Common Retirement Fund lifted its position in Liquidia by 124.6% during the fourth quarter. New York State Common Retirement Fund now owns 19,312 shares of the company’s stock valued at $232,000 after purchasing an additional 10,714 shares during the period. BNP Paribas Financial Markets lifted its position in Liquidia by 19.1% during the fourth quarter. BNP Paribas Financial Markets now owns 104,933 shares of the company’s stock valued at $1,262,000 after purchasing an additional 16,843 shares during the period. Jump Financial LLC bought a new position in Liquidia during the fourth quarter valued at approximately $1,933,000. Finally, Trexquant Investment LP bought a new position in Liquidia during the fourth quarter valued at approximately $770,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on LQDA. Needham & Company LLC restated a “buy” rating and set a $25.00 price objective on shares of Liquidia in a research report on Monday, August 19th. Raymond James upgraded shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a research report on Monday, August 19th. BTIG Research decreased their price target on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a research report on Monday, August 19th. Oppenheimer assumed coverage on shares of Liquidia in a research report on Tuesday, June 25th. They issued a “market perform” rating on the stock. Finally, HC Wainwright decreased their price target on shares of Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and an average target price of $23.14.

Insider Activity

In other news, CFO Michael Kaseta sold 3,906 shares of the firm’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the sale, the chief financial officer now directly owns 312,389 shares in the company, valued at approximately $3,914,234.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Michael Kaseta sold 3,906 shares of the firm’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $48,942.18. Following the completion of the transaction, the chief financial officer now directly owns 312,389 shares of the company’s stock, valued at $3,914,234.17. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 8,053 shares of the firm’s stock in a transaction on Friday, July 12th. The shares were sold at an average price of $12.53, for a total transaction of $100,904.09. Following the transaction, the chief executive officer now directly owns 818,932 shares of the company’s stock, valued at $10,261,217.96. The disclosure for this sale can be found here. Insiders have sold 21,437 shares of company stock worth $268,549 in the last three months. Company insiders own 31.60% of the company’s stock.

Liquidia Price Performance

Shares of LQDA stock traded down $0.03 on Friday, hitting $9.51. 815,141 shares of the stock traded hands, compared to its average volume of 998,645. The firm has a market cap of $726.70 million, a price-to-earnings ratio of -6.10 and a beta of 0.32. Liquidia Co. has a 52 week low of $5.71 and a 52 week high of $16.99. The firm has a 50 day simple moving average of $11.56 and a two-hundred day simple moving average of $13.05.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $3.66 million for the quarter, compared to the consensus estimate of $7.92 million. Liquidia had a negative net margin of 674.42% and a negative return on equity of 177.83%. Sell-side analysts forecast that Liquidia Co. will post -1.39 EPS for the current year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).